Loading clinical trials...
Loading clinical trials...
Phase 2 Placebo-Controlled, Single-Site, Single-Blind Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
Conditions
Interventions
Ciraparantag
Placebo
+1 more
Locations
1
United States
Frontage Clinical Services Inc.
Secaucus, New Jersey, United States
Start Date
May 8, 2017
Primary Completion Date
November 12, 2019
Completion Date
November 12, 2019
Last Updated
September 2, 2025
NCT06716502
NCT00090662
NCT07310264
NCT06290258
NCT07483606
NCT06342713
Lead Sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions